Recommended

New webinar: The path to optimisation in pharmaceutical microbiology

New webinar in 2025: Trends for life sciences quality leaders in 2025 – mastering what matters! Register your details now to secure your place!

New upcoming webinar: Navigating pharmaceutical environmental monitoring in a changing industry! Register your details today!

Explore our new Pharma Horizons: Sustainability report for key developments in the pharmaceutical industry!

Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps

<iframe src="https://www.googletagmanager.com/ns.html?id=GTM-P89LTFL" height="0" width="0" style="display:none;visibility:hidden"></iframe>

List view / Grid view

Norbert Bischofberger

virologically

virologically

Gilead submits drug application to FDA for HIV treatment

Gilead has submitted a new drug application to the US…

15 June 2017 | By Niamh Marriott (European Pharmaceutical Review)

Gilead has submitted a new drug application to the US FDA for treatments of HIV.

Gilead to stop Phase 3 Study 116 of Idelalisib in chronic lymphocytic leukemia early because of positive risk benefit

"We are pleased that idelalisib has shown a clinically meaningful…

9 October 2013 | By Gilead

"We are pleased that idelalisib has shown a clinically meaningful benefit for patients..."

Gilead reports interim data from Phase 2 LONESTAR study

Gilead Sciences announced plans to initiate a third Phase 3…

2 May 2013 | By Gilead Sciences

Gilead Sciences announced plans to initiate a third Phase 3 clinical trial...

Gilead announces full 24-week Phase 2 results for once-daily single tablet HIV regimen containing novel prodrug TAF

TAF-based regimen now in Phase 3 development...

5 March 2013 | By Gilead Sciences

TAF-based regimen now in Phase 3 development...

Gilead’s sofosbuvir for hepatitis C meets primary endpoint in fourth pivotal Phase 3 study

Topline results from the Phase 3 FUSION study...

19 February 2013 | By Gilead Sciences

Topline results from the Phase 3 FUSION study...

Gilead announces sustained virologic response rates from two Phase 3 studies of sofosbuvir for hepatitis C

Topline results from two Phase 3 studies...

4 February 2013 | By Gilead Sciences, Inc.

Topline results from two Phase 3 studies...

Gilead initiates Phase 3 clinical program for tenofovir alafenamide

“We are pleased to move TAF into Phase 3 clinical…

24 January 2013 | By Gilead Sciences

“We are pleased to move TAF into Phase 3 clinical research...”

Gilead provides update on Hepatitis C development programs

Gilead Sciences announced several updates regarding its late-stage pipeline candidates…

7 January 2013 | By Gilead Sciences

Gilead Sciences announced several updates regarding its late-stage pipeline candidates for the treatment of chronic HCV infection...

Gilead Sciences to acquire YM BioSciences

Gilead Sciences and YM BioSciences announced that the companies have…

12 December 2012 | By Gilead Sciences

Gilead Sciences and YM BioSciences announced that the companies have signed a definitive agreement...

European Commission approves Viread®

Gilead Sciences announced that the European Commission has granted marketing…

27 November 2012 | By Gilead Sciences, Inc.

Gilead Sciences announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread®...

Gilead announces sustained virologic response rate of 78% from Phase 3 study of sofosbuvir for genotype 2/3 hepatitis C infected patients

Gilead Sciences announced topline results from the Phase 3 POSITRON…

27 November 2012 | By Gilead Sciences

Gilead Sciences announced topline results from the Phase 3 POSITRON study...

Gilead’s once-daily novel prodrug for the treatment of HIV meets 24-week primary objective in Phase 2 study

Data support tenofovir alafenamide fumarate as component of future single…

31 October 2012 | By Gilead Sciences

Data support tenofovir alafenamide fumarate as component of future single tablet HIV regimens...

Gilead ’s Boosting Agent Cobicistat for HIV Therapy as Effective as Ritonavir in Pivotal Phase 3 Study

Full clinical trial results from a pivotal Phase 3 study...

24 July 2012 | By Gilead Sciences, Inc.

Full clinical trial results from a pivotal Phase 3 study...

U.S. FDA approves Gilead ’s Truvada® for reducing the risk of acquiring HIV

The U.S. FDA has approved once-daily oral Truvada®...

16 July 2012 | By Gilead Sciences

The U.S. FDA has approved once-daily oral Truvada®...

Gilead submits New Drug Application to U.S. FDA for boosting agent cobicistat

Gilead Sciences has submitted a New Drug Application to the…

28 June 2012 | By Gilead Sciences

Gilead Sciences has submitted a New Drug Application to the U.S. FDA for marketing approval of cobicistat...

© Russell Publishing Limited, 2010-2024. All rights reserved.

Website development by e-Motive Media Limited.

Cookie Settings

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Cookie	Description
cookielawinfo-checkbox-advertising-targeting	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.

Cookie	Description
cf_ob_info	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	This cookie is set by Youtube and is used to track the views of embedded videos.

Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.

Cookie	Description
bcookie	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	This cookie is set by LinkedIn and used for routing.
lissc	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Advertising & Targeting

Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.

Cookie	Description
advanced_ads_browser_width	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.